Shopping Cart
- Remove All
- Your shopping cart is currently empty
RD162 is a non-steroidal antiandrogen (NSAA) specifically binding to the androgen receptor (AR).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 37 € | In Stock | |
5 mg | 115 € | In Stock | |
10 mg | 187 € | In Stock | |
25 mg | 392 € | In Stock | |
50 mg | 584 € | In Stock | |
100 mg | 832 € | In Stock | |
1 mL x 10 mM (in DMSO) | 139 € | In Stock |
Description | RD162 is a non-steroidal antiandrogen (NSAA) specifically binding to the androgen receptor (AR). |
In vitro | RD162 has little to no binding to the progesterone, estrogen, or glucocorticoid receptors. RD162 (1-10 μM) suppressed growth and induces apoptosis in the human prostate cancer cell line VCaP which had endogenous AR gene amplification[1]. |
In vivo | RD162 (20 mg/kg) is ∼50 percent bioavailable after oral delivery with a serum half-life of about 30 hours. RD162 (10 mg/kg; oral gavage) causes all tumors regressed. RD162 (0.1, 1, 10 mg/kg; oral gavage) consistently reduces luciferase activity with 10 mg/kg/day human LNCaP/AR xenografts grown in castrated male mice whereas lower doses of 0.1 and 1.0 mg/kg/day has minimal effect. RD162 substantially reduces cellular proliferation after 5 days[1]. |
Molecular Weight | 476.45 |
Formula | C22H16F4N4O2S |
Cas No. | 915087-27-3 |
Smiles | O=C1C2(N(C(=S)N1C3=CC(C(F)(F)F)=C(C#N)C=C3)C4=CC(F)=C(C(NC)=O)C=C4)CCC2 |
Relative Density. | 1.55 g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (104.94 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.